SCHEMBL489489

SCHEMBL489489

CC(C)(C)OC(=O)N[C@@H](CC(=O)O)Cc1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.70
APP P05067 4/20 0.57
CTSS P25774 3/20 0.56
CTSK P43235 2/20 0.56
CTSL P07711 1/20 0.56
CTSB P07858 1/20 0.56
ACE P12821 1/20 0.54
KLK5 Q9Y337 2/20 0.53
SYK P43405 1/20 0.52
CYP3A4 P08684 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1519945 1.00 ATM (0.70) ATMAPPCTSSCTSKCTSL
SCHEMBL489490 1.00 ATM (0.70) ATMAPPCTSSCTSKCTSL
SCHEMBL825492 0.92 CTSS (0.61) ATMAPPCTSSCTSKCTSL
SCHEMBL3699140 0.92 CTSS (0.61) ATMAPPCTSSCTSKCTSL
SCHEMBL28113260 0.90 ATM (0.68) ATMAPPCTSSCTSKCTSL
SCHEMBL28113259 0.90 ATM (0.68) ATMAPPCTSSCTSKCTSL
SCHEMBL2617274 0.89 ATM (0.58) ATMAPPCTSSCTSKCTSL
SCHEMBL5888032 0.89 ATM (0.58) ATMAPPCTSSCTSKCTSL
SCHEMBL17376003 0.89 ATM (0.67) ATMAPPCTSSCTSKCTSL
SCHEMBL7239876 0.89 ATM (0.67) ATMAPPCTSSCTSKCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116874803-A Antibacterial dendritic polyester polymer and preparation method and application thereof 清华大学深圳国际研究生院 2023-10-13 CN claimed
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PEPTIDREAM INC (JP) 2026-01-15 US disclosed
EP-4534524-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PeptiDream Inc. (JP) 2025-04-09 EP disclosed
CN-116874803-A Antibacterial dendritic polyester polymer and preparation method and application thereof 清华大学深圳国际研究生院 2023-10-13 CN disclosed
US-20220411362-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN THERAPEUTICS, INC. 2022-12-29 US disclosed
WO-2017222083-A1 NOVEL COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-12-28 WO disclosed
CN-103582644-B Phthalazinone-Pyrrolopyrimidine Carboxamide Derivatives 塔科达有限责任公司 2016-07-20 CN disclosed
US-20160152576-A9 AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA, INC. (US) 2016-06-02 US disclosed
US-20160108049-A1 Novel Phthalazinone-Pyrrolopyrimidinecarboxamide Derivatives ASTRAZENECA AB (SE) 2016-04-21 US disclosed
US-9273008-B2 Dual-acting imidazole antihypertensive agents THERAVANCE BIOPHARMA R&D IP, LLC (US) 2016-03-01 US disclosed
EP-0869786-B1 PHARMACEUTICAL COMPOUNDS LILLY CO ELI (US) 2003-03-05 EP disclosed
US-20020128185-A1 Pharmaceutical compounds HAWAII, UNIVERSITY OF 2002-09-12 US disclosed
US-6376230-B1 Stereoselective process for producing intermediates of cryptophycins ELI LILLY AND COMPANY 2002-04-23 US disclosed
EP-1127055-A2 STEREOSELECTIVE PROCESS FOR PRODUCING CRYPTOPHYCINS ELI LILLY AND COMPANY (US) 2001-08-29 EP disclosed
EP-1078919-A1 SYNTHESIS OF $g(a)-AMINO-$g(a)',$g(a)'-DIHALOKETONES AND PROCESS FOR THE PREPARATION OF $g(b)-AMINO ACID DERIVATIVES BY THE USE OF THE SAME KANEKA CORPORATION (JP) 2001-02-28 EP disclosed
WO-2000034252-A2 PROCESS FOR THE PREPARATION OF CRYPTOPHYCIN DERIVATIVES ELI LILLY AND COMPANY (US) 2000-06-15 WO disclosed
WO-2000023429-A2 STEREOSELECTIVE PROCESS FOR PRODUCING CRYPTOPHYCINS ELI LILLY AND COMPANY (US) 2000-04-27 WO disclosed
EP-0869786-A4 PHARMACEUTICAL COMPOUNDS LILLY CO ELI (US) 1999-04-14 EP disclosed
EP-0869786-A1 PHARMACEUTICAL COMPOUNDS ELI LILLY AND COMPANY (US) 1998-10-14 EP disclosed
WO-1997023211-A1 PHARMACEUTICAL COMPOUNDS ELI LILLY AND COMPANY (US) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF NSUN3, BCAT1, SLC43A1 ATM 4553/4885APP 4712/4885CTSS 4022/4885
US-20020128185-A1 Pharmaceutical compounds XPO5, XPOT, XPO1 ATM 2247/4885APP 4296/4885CTSS 1721/4885
US-20220411362-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) PRKCA, PRKCH, PRKCB ATM 570/4885APP 4745/4885CTSS 3848/4885
US-20160152576-A9 AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, AKT3 ATM 150/4885APP 4101/4885CTSS 3033/4885
US-20160108049-A1 Novel Phthalazinone-Pyrrolopyrimidinecarboxamide Derivatives PDE4A, PDE4B, PDE5A ATM 3781/4885APP 3751/4885CTSS 1616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.